The United Laboratories International Holdings Limited

中/EN
中文繁體 English
  • Investor Relations
    IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
  • Corporate
Investor Relations
  • IR Home
  • Corporate Overview
  • Financial Highlights
  • Financial Reports
  • ESG Reports
  • Regulatory Filings
  • Press Releases
  • Company
    Presentations
  • Stock Quotes &
    Charts
  • Analyst Coverage
  • FAQs
  • IR Contact

Press Releases

2022
Please select
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
AUG
24
The United Laboratories International Holdings Limited Announces 2022 Interim Results, Ebitda up 8.0% to Rmb1,141 Million, Interim Dividend up 25.0% to RMB5 Cents Per Share, Sales Volume of Insulin Series Grows Steadily, Insulin Degludec/Insulin Aspart Injection Receive Clinical Trial Approval
MAR
24
The United Laboratories International Holdings Limited Announces 2021 Annual Results, Continuous Improvement in Profitability, Proposed Final Dividend and Special Dividend totaled RMB0.1 Per Share
Disclaimer | Sitemap

Copyright © 2019 The United Laboratories International Holdings Limited. All rights reserved.